Clinical Trial Detail

NCT ID NCT02616393
Title Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kadmon Corporation, LLC
Indications

lung non-small cell carcinoma

Therapies

Tesevatinib

Age Groups: adult

No variant requirements are available.